Molecular imaging of immunotherapy targets in cancer

Journal of Nuclear Medicine

Volumn 57, Issue 10, 2016, Pages 1487-1492

  Ehlerding, Emily B ^a   England, Christopher G ^a   McNeel, Douglas G ^a,b   Cai, Weibo ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

CTLA 4; Immune checkpoints; Immunotherapy; PD 1; PD L1; Positron emission tomography (PET)

Indexed keywords

ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB;

BLADDER CANCER; CANCER IMMUNOTHERAPY; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DIAGNOSTIC IMAGING; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; HUMANS; IMMUNOTHERAPY; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84991372950     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.177493     Document Type: Review

References (40)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
2. Topalian SL, Drake Charles G, Pardoll Drew M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450-461.
3. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98-106.
4. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71:5670-5677.
5. Madore J, Vilain RE, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015;28:245-253.
6. Geynisman DM, Chien C-R, Smieliauskas F, Shen C, Shih Y-CT. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother. 2014;10:3415-3424.
7. 18F-FDG-PET in patients with advanced stage renal cell carcinoma. World J Urol. 2013;31:841-846.
8. Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014;21:231-237.
9. Kleffel S, Posch C, Barthel Steven R, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162:1242-1256.
10. Ivashko IN, Kolesar JM. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. Am J Health Syst Pharm. 2016;73:193-201.
11. Tan M, Quintal L. Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. J Clin Pharm Ther. 2015;40:504-507.
12. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020-1030.
13. Natarajan A, Mayer AT, Xu L, Reeves RE, Gano J, Gambhir SS. Novel radiotracer for immunoPET imaging of PD-1 checkpoint expression on tumor infiltrating lymphocytes. Bioconjug Chem. 2015;26:2062-2069.
14. Hettich M, Braun F, Bartholoma MD, Schirmbeck R, Niedermann G. High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics. 2016;6:1629-1640.
15. 89Zr-labeled pembrolizumab. J Nucl Med. In press.
16. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847-856.
17. Ahmad SM, Borch TH, Hansen M, Andersen MH. PD-L1-specific T cells. Cancer Immunol Immunother. 2016;65:797-804.
18. Maute RL, Gordon SR, Mayer AT, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA. 2015;112:E6506-E6514.
19. Chatterjee S, Lesniak WG, Gabrielson M, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget. 2016;7:10215-10227.
20. Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567.
21. Heskamp S, Hobo W, Molkenboer-Kuenen JDM, et al. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res. 2015;75:2928-2936.
22. Josefsson A, Nedrow JR, Park S, et al. Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Cancer Res. 2016;76:472-479.
23. Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125:3377-3383.
24. Antczak A, Pastuszak-Lewandoska D, Górski P, et al. CTLA-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer. BioMed Res Int. 2013;2013:576486.
25. Kim DW, Trinh VA, Hwu W-J. Ipilimumab in the treatment of advanced melanoma: a clinical update. Expert Opin Biol Ther. 2014;14:1709-1718.
26. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616-622.
27. 64Cu-DOTA-Anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One. 2014;9:e109866.
28. McCracken MN, Vatakis DN, Dixit D, McLaughlin J, Zack JA, Witte ON. Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging. J Clin Invest. 2015;125:1815-1826.
29. Larimer BM, Wehrenberg-Klee E, Caraballo A, Mahmood U. Quantitative CD3 PET imaging predicts tumor growth response to anti-CTLA-4 therapy. J Nucl Med. May 26, 2016 [Epub ahead of print].
30. Tavare R, Escuin-Ordinas H, McCracken M, et al. Detection of antibody therapy-induced anti-tumor immune responses using anti-CD8 immuno-pet [abstract]. J Immunother Cancer. 2015;3(suppl 2):P391.
31. Tavaré R, Escuin-Ordinas H, Mok S, et al. An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 2016;76:73-82.
32. Das R, Verma R, Sznol M, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015;194:950-959.
33. Boswell CA, Mundo EE, Zhang C, et al. Differential effects of predosing on tumor and tissue uptake of an111 In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med. 2012;53:1454-1461.
34. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498-e509.
35. Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett. 2015;365:23-29.
36. Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21:634-642.
37. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-1813.
38. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
39. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837-1846.
40. Sidaway P. Bladder cancer: Atezolizumab effective against advanced-stage disease. Nat Rev Urol. 2016;13:238.